This page is the continuation of references in support of Section 8b Breast Cancer Treatment.
EBCTCG (Early Breast Cancer Trialists’ Collaborative Group), McGale, P., Taylor, C., Correa, C., et al. (2014). Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: meta-analysis of individual patient data for 8135 women in 22 randomised trials. Lancet 383(9935), 2127-35. (Retrieved November 26th 2014): http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(14)60488-8/fulltext
Farmer, H., McCabe, N., Lord, C.J. et al. (2005). Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 434, 917-21. (Retrieved November 26th 2014): http://www.ncbi.nlm.nih.gov/pubmed/15829967
Hughes, L.L., Wang, M., Page, D.L., Gray, R., Solin, L.J., Davidson, N.E., Lowen, M.A., Ingle, J.N., Recht, A., Wood, W.C. (2009). Local excision alone without irradiation for ductal carcinoma in situ of the breast: a trial of the Eastern Cooperative Oncology Group. J Clin Oncol 27(32), 5319. (Retrieved November 6th 2014): http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2773217/
Miller K,, Wang, M., Gralow, J. et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med. 2007;357(26):2666–2676. (Retrieved November 27th 2014): http://www.nejm.org/doi/full/10.1056/NEJMoa072113
National Comprehensive Cancer Network (NCCN). NCCN Clinical practice guidelines in oncology. Retrieved November 6th 2014): http://www.nccn.org/professionals/physician_gls/f_guidelines.asp
Oppong, B.A., King, T.A. (2011). Recommendations for women with lobular carcinoma in situ (LCIS). Oncology 25(11), 1051-6. (Retrieved November 26th 2014): https://www.ncbi.nlm.nih.gov/pubmed/22106556
Staley, H., McCallum, I., Bruce, J. (2012). Postoperative tamoxifen for ductal carcinoma in situ. Cochrane Database Syst Rev 10, CD007847. (Retrieved November 6th 2014): https://www.ncbi.nlm.nih.gov/pubmed/23076938